Q1 25 EPS
$2.84
BEAT +4.03%
Est. $2.73
Q1 25 Revenue
$5.87B
BEAT +3.07%
Est. $5.69B
vs S&P Since Q1 25
-47.6%
TRAILING MARKET
SYK -20.4% vs S&P +27.2%
Market Reaction
Did SYK Beat Earnings? Q1 2025 Results
Stryker opened 2025 on a strong footing, posting first-quarter revenue of $5.87 billion, up 11.9% year-over-year and ahead of the $5.69 billion consensus estimate by 3.07%, while adjusted EPS of $2.84 beat the $2.73 Wall Street forecast by 4.03% and … Read more Stryker opened 2025 on a strong footing, posting first-quarter revenue of $5.87 billion, up 11.9% year-over-year and ahead of the $5.69 billion consensus estimate by 3.07%, while adjusted EPS of $2.84 beat the $2.73 Wall Street forecast by 4.03% and represented 13.6% growth from the prior year. The standout driver was broad-based volume momentum, with organic net sales advancing 10.1% on the back of 9.4% unit volume gains across both segments; the newly integrated Vascular business, reflecting the Inari Medical acquisition, surged 31.0% to $406 million and anchored MedSurg and Neurotechnology's 13.4% reported growth. Adjusted operating margins expanded 100 basis points to 22.9%, underscoring operational discipline even as acquisition-related charges weighed heavily on GAAP results. Looking ahead, Stryker raised its full-year organic sales growth guidance to 8.5%-9.5% while holding adjusted EPS guidance at $13.20 to $13.45, a range that absorbs an estimated $200 million tariff headwind that management acknowledged would otherwise have supported higher earnings.
Key Takeaways
- • 10.1% organic net sales growth driven by 9.4% unit volume increases and 0.7% higher prices
- • Strong procedural volumes across MedSurg, Neurotechnology, and Orthopaedics
- • Demand for capital products
- • Commercial execution across end markets
- • Vascular segment grew 31.0% driven by Inari Medical acquisition
- • U.S. sales growth of 13.4% outpaced international growth of 7.3%
- • Adjusted operating income margin expanded 100 bps to 22.9%
SYK YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
SYK Revenue by Segment
With YoY comparisons, source: SEC Filings
SYK Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our 2024 momentum continued into the first quarter as we delivered double-digit organic sales growth and continued to expand adjusted operating margins. We remain confident in our sales and earnings power for 2025, fueled by the strength of procedural volumes, demand for our capital products and our commercial execution.”
— Kevin A. Lobo, Q1 2025 Earnings Press Release
SYK Earnings Trends
SYK vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
SYK EPS Trend
Earnings per share: estimate vs actual
SYK Revenue Trend
Quarterly revenue: estimate vs actual
SYK Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.60 | — | $6.02B | -4.89% |
| Q4 25 BEAT FY | $4.40 | $4.47 | +1.59% | $7.17B | +0.98% |
| FY Full Year | $13.56 | $13.63 | +0.53% | $25.12B | +0.28% |
| Q3 25 BEAT | $3.13 | $3.19 | +1.86% | $6.06B | +0.20% |
| Q2 25 BEAT | $3.07 | $3.13 | +1.94% | $6.02B | +1.57% |
| Q1 25 BEAT | $2.73 | $2.84 | +4.03% | $5.87B | +3.07% |